XP Chemistries AB (SE:XPC)
:XPC
Want to see SE:XPC full AI Analyst Report?
Top Page
XP Chemistries AB
(XPC)
Select Model
Select Model
Rating:47Neutral
Price Target:
kr0.17
▼(-3.33% Downside)
Action:ReiteratedDate:05/05/26
The score is primarily constrained by persistent losses and continued negative free cash flow, despite a debt-free balance sheet. Technicals add pressure with the stock trading below key moving averages and negative MACD, while valuation is also weakened by negative earnings and no dividend support.
Positive Factors
Debt-free balance sheet
A zero-debt balance sheet provides durable financial flexibility and low refinancing risk, allowing the company to prioritize operating investment or absorb shocks without scheduled interest burdens. Over 2–6 months this underpins strategic options despite ongoing losses.
Negative Factors
Persistent operating losses
Chronic operating and net losses erode capital and restrict strategic choices. Over months this reduces reinvestment capacity, complicates hiring and scaling, and can force dilutive financing or cost cuts, making a durable path to profitability more uncertain.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A zero-debt balance sheet provides durable financial flexibility and low refinancing risk, allowing the company to prioritize operating investment or absorb shocks without scheduled interest burdens. Over 2–6 months this underpins strategic options despite ongoing losses.
Read all positive factors
XP Chemistries AB (XPC) vs. iShares MSCI Sweden ETF (EWD)
Market Cap
kr56.04M
Dividend YieldN/A
Average Volume (3M)792.79K
Price to Earnings (P/E)―
Beta (1Y)0.64
Revenue GrowthN/A
EPS GrowthN/A
CountrySE
Employees2
SectorBasic Materials
Sector Strength58
IndustryChemicals
Share Statistics
EPS (TTM)-0.04
Shares Outstanding313,976,300
10 Day Avg. Volume516,841
30 Day Avg. Volume792,795
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)0.97
Price to Sales (P/S)109.05
P/FCF Ratio-3.89
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.02
Revenue Forecast (FY)kr10.26M
XP Chemistries AB Business Overview & Revenue Model
Company Description
XP Chemistries AB, a biotechnology company, develops and produces forest-based capsaicin and analogues. It offers animal feed ingredients, cosmetic ingredients, pure capsaicinoids, and self-defense liquid and ingredients. The company was incorpora...
XP Chemistries AB Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
22
Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 327.39K | 283.94K | 663.68K | 1.06M | 279.39K |
| Gross Profit | 127.68K | 328.97K | 335.61K | 488.98K | 149.56K |
| EBITDA | -9.05M | -7.52M | -8.70M | -8.73M | -5.01M |
| Net Income | -8.52M | -7.13M | -8.04M | -7.92M | -4.55M |
Balance Sheet | |||||
| Total Assets | 38.07M | 22.72M | 27.20M | 30.65M | 34.39M |
| Cash, Cash Equivalents and Short-Term Investments | 15.23M | 2.15M | 7.83M | 15.20M | 21.40M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.13M | 1.16M | 1.51M | 1.58M | 3.09M |
| Stockholders Equity | 36.94M | 21.56M | 25.69M | 29.07M | 31.30M |
Cash Flow | |||||
| Free Cash Flow | -9.18M | -8.53M | -11.41M | -11.80M | -8.13M |
| Operating Cash Flow | -8.85M | -7.69M | -9.08M | -9.85M | -4.99M |
| Investing Cash Flow | -332.30K | -834.96K | -2.33M | -1.95M | -6.31M |
| Financing Cash Flow | 22.26M | 2.85M | 4.04M | 5.60M | 32.70M |
XP Chemistries AB Peers Comparison
UnderperformOutperform
Sector (61)
SE:XPC
XP Chemistries AB
0.18
-0.18
-50.56%
DE:NC4
Nexam Chemical Holding AB
0.19
-0.09
-31.56%
DE:5L80
Svenska Aerogel Holding AB
0.03
-0.11
-78.77%
DE:284
Serstech AB
0.03
-0.03
-47.69%
DE:A6X
aXichem AB Class A
0.08
-0.04
-33.05%
DE:0CF
OrganoClick AB
0.04
-0.08
-66.94%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.